A non-retinoid triazolopyrimidine RBP4 antagonist for the treatment of Stargardt disease
K. Alison Rinderspacher, András Váradi, Bóglárka Rácz, Andrew S. Wasmuth, Shi-Xian Deng, Patricia Weber, Donald W. Landry, Peter R Bernstein, Konstantin E. Petrukhin
This paper describes a non-retinoid RBP4 antagonist, AKR-XI-85, that reduces lipofuscin accumulation in a mouse model of Stargardt disease.
bioRxiv · Sep 21, 2026 · PreprintPharmacology & Toxicology